The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2023 | AMBER: anti-TIM3 antibody reverses T-cell exhaustion in NSCLC
Diwakar Davar, MD, University of Pittsburgh School of Medicine, Pittsburgh, PA, discusses findings from the AMBER trial (NCT02817633) of cobolimab, an anti-TIM-3 monoclonal antibody, alone or with PD-1 inhibitors in patients with non-small cell lung cancer (NSCLC). Cobolimab plus dostarlimab combination therapy in patients with NSCLC previously treated with anti-PD(L)-1 therapy returned some evidence of efficacy and progression-free survival with responders having higher expression of TIM3. The treatment was safe and produced pharmacodynamic evidence that the drug worked as intended, with increased T-cell engagement. The Phase II COSTAR Lung (NCT04655976) trial is administering this therapy in addition to docetaxel to assess its impact. This interview took place at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
